Advancing the Treatment of Patients With Myelofibrosis

Click HERE to Access Webinar OnDemand Recording 

Click HERE to Access CME Evaluation 

Advancing the Treatment of Patients With Myelofibrosis

Presented By: Aaron T. Gerds, MD, MS – Associate Professor of Medicine and Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute

Learning Objectives:

• Review the disease burden experienced by patients with myelofibrosis.
• Initiate treatment based on patient prognosis and characteristics.
• Implement strategies, including modifying therapy, to overcome treatment barriers.
• Describe the safety and efficacy of emerging novel therapies for myelofibrosis.

Aaron Gerds, MD, MS, is an associate professor of medicine and deputy director for clinical research at the Cleveland Clinic Taussig Cancer Institute and medical director of the Clinical Research Office for Case Western Reserve University’s Case Comprehensive Cancer Center. Dr. Gerds received his medical degree from Loyola University Chicago Stritch School of Medicine where he also completed his residency. He was awarded a fellowship in hematology/oncology by the University of Washington’s Fred Hutchinson Cancer Center in Seattle.
Dr. Gerds’ clinical and research interests focus on optimizing current treatments, and developing new therapies for patients with myeloproliferative disorders and other myeloid neoplasia. He serves as principal investigator for a number of clinical trials.
An active member of the American Society of Hematology, Dr. Gerds participates in both the organization’s Advocacy Leadership Institute and Clinical Research Training Institute. He also chairs the National Comprehensive Cancer Network’s MPN guidelines panel. Dr. Gerds is the author or coauthor of numerous journal articles and abstracts and serves as editor-in-chief of ASH Clinical News.